These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33981224)

  • 21. FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC.
    Chen X; Chen J; Feng W; Huang W; Wang G; Sun M; Luo X; Wang Y; Nie Y; Fan D; Wu K; Xia L
    Theranostics; 2023; 13(4):1401-1418. PubMed ID: 36923538
    [No Abstract]   [Full Text] [Related]  

  • 22. FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis.
    Lang L; Xiong Y; Prieto-Dominguez N; Loveless R; Jensen C; Shay C; Teng Y
    J Exp Clin Cancer Res; 2021 Mar; 40(1):93. PubMed ID: 33691750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
    Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
    Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Making way for suppressing the FGF19/FGFR4 axis in cancer.
    Prieto-Dominguez N; Shull AY; Teng Y
    Future Med Chem; 2018 Oct; 10(20):2457-2470. PubMed ID: 30325210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bromocriptine sensitivity in bromocriptine-induced drug-resistant prolactinomas is restored by inhibiting FGF19/FGFR4/PRL.
    Zhu Z; Hu B; Zhu D; Li X; Chen D; Wu N; Rao Q; Zhang Z; Wang H; Zhu Y
    J Endocrinol Invest; 2024 Jun; ():. PubMed ID: 38926262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
    Kanzaki H; Chiba T; Ao J; Koroki K; Kanayama K; Maruta S; Maeda T; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Ogasawara S; Suzuki E; Ooka Y; Muroyama R; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Mimura N; Kato J; Zen Y; Ohtsuka M; Iwama A; Kato N
    Sci Rep; 2021 Mar; 11(1):5303. PubMed ID: 33674622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis.
    Chen T; Liu H; Liu Z; Li K; Qin R; Wang Y; Liu J; Li Z; Gao Q; Pan C; Yang F; Zhao W; Zhang Z; Xu Y
    Oncogene; 2021 Jul; 40(30):4941-4953. PubMed ID: 34163030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pancreatic Cancer.
    Sasaki N; Gomi F; Yoshimura H; Yamamoto M; Matsuda Y; Michishita M; Hatakeyama H; Kawano Y; Toyoda M; Korc M; Ishiwata T
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma.
    Shen B; Shi JP; Zhu ZX; He ZD; Liu SY; Shi W; Zhang YX; Ying HY; Wang J; Xu RF; Fang F; Chang HX; Chen Z; Zhang NN
    Mol Cancer Ther; 2023 Dec; 22(12):1479-1492. PubMed ID: 37710057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alteration in the serum concentrations of FGF19, FGFR4 and βKlotho in patients with thyroid cancer.
    Motylewska E; Stępień T; Borkowska M; Kuzdak K; Siejka A; Komorowski J; Stępień H; Ławnicka H
    Cytokine; 2018 May; 105():32-36. PubMed ID: 29438906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
    Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM
    Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity.
    Bartz R; Fukuchi K; Ohtsuka T; Lange T; Gruner K; Watanabe I; Hayashi S; Oda Y; Kawaida R; Komori H; Kashimoto Y; Wirtz P; Mayer JA; Redondo-Müller M; Saito S; Takahashi M; Hanzawa H; Imai E; Martinez A; Hanai M; Häussinger D; Chapman RW; Agatsuma T; Bange J; Abraham R
    Mol Cancer Ther; 2019 Oct; 18(10):1832-1843. PubMed ID: 31350344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.
    Drafahl KA; McAndrew CW; Meyer AN; Haas M; Donoghue DJ
    PLoS One; 2010 Dec; 5(12):e14412. PubMed ID: 21203561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
    Miura S; Mitsuhashi N; Shimizu H; Kimura F; Yoshidome H; Otsuka M; Kato A; Shida T; Okamura D; Miyazaki M
    BMC Cancer; 2012 Feb; 12():56. PubMed ID: 22309595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
    Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
    Weiss A; Adler F; Buhles A; Stamm C; Fairhurst RA; Kiffe M; Sterker D; Centeleghe M; Wartmann M; Kinyamu-Akunda J; Schadt HS; Couttet P; Wolf A; Wang Y; Barzaghi-Rinaudo P; Murakami M; Kauffmann A; Knoepfel T; Buschmann N; Leblanc C; Mah R; Furet P; Blank J; Hofmann F; Sellers WR; Graus Porta D
    Mol Cancer Ther; 2019 Dec; 18(12):2194-2206. PubMed ID: 31409633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.
    Li X; Lu W; Kharitonenkov A; Luo Y
    J Intern Med; 2024 Mar; 295(3):292-312. PubMed ID: 38212977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of Fibroblast Growth Factor Receptor 4 by Helicobacter pylori via Signal Transducer and Activator of Transcription 3 With a Feedforward Activation Loop Involving SRC Signaling in Gastric Cancer.
    Zhang X; Soutto M; Chen Z; Bhat N; Zhu S; Eissmann MF; Ernst M; Lu H; Peng D; Xu Z; El-Rifai W
    Gastroenterology; 2022 Sep; 163(3):620-636.e9. PubMed ID: 35588797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104.
    Li F; Li Z; Han Q; Cheng Y; Ji W; Yang Y; Lu S; Xia W
    Oncogene; 2020 Apr; 39(17):3507-3521. PubMed ID: 32111983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1.
    Triantis V; Saeland E; Bijl N; Oude-Elferink RP; Jansen PL
    Hepatology; 2010 Aug; 52(2):656-66. PubMed ID: 20683963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.